Table 3 Summary of bioinformatics and literature evidence for UBXDF in cancers
GENE | Cancer type | Abbreviations | Clinical evidence from bioinformatics | Clinical evidence from the literature | |||
|---|---|---|---|---|---|---|---|
Expression in cancer (Additional file 1: Figure S2A) | Survival (Fig. 2A) | Immune score (Additional file 1: Figure S3, Table S3A) | in vitro (Table 2), in vivo (Table 1), clinical, targeted medicine | ||||
FAF1 | Colorectal cancer | COAD | Overexpression | NS* | Positive | Negative | Mediates apoptosis. |
FAF1 | Breast cancer | BRCA | Underexpression | NS | Positive | NS | Mediates migration and invasion. Mediates metastasis and invasion. Mediates migration, invasion and metastasis. Inhibits metastasis. |
FAF1 | Cervical cancer | CESC | – | NS | Positive | NS | Mediates tumour formation. |
FAF1 | Clear cell renal cell carcinoma | KIRC | Underexpression | Protective | Positive (RNAss) | Negative | Mediates growth. |
FAF1 | Lung cancer | LUAD and LUSC | Overexpression | NS | Positive | Negative (LUAD) | Mediates growth, migration, invasion and apoptosis. |
FAF1 | Gastric cancer | STAD | Overexpression | NS | Positive | Negative | Mediates cell death and apoptosis. Mediates apoptosis, proliferation and growth. Mediates apoptosis, proliferation and growth. |
FAF1 | Non-small cell lung carcinomas | LUAD | Overexpression | NS | Positive | Negative | Mediates proliferation, invasion, migration, cell cycle arrest and apoptosis. Reduces tumour volume and weight. |
FAF1 | Ovarian cancer | OV | – | NS | Positive (RNAss) | NS | Mediates cell survival. |
FAF1 | Prostate cancer | PRAD | NS | NS | Positive | NS | Mediates apoptosis. |
FAF1 | Malignant mesothelioma | MESO | – | Risk | Positive (DNAss) | NS | Inhibits Malignant mesothelioma development. |
FAF1 | Sarcoma | SARC | – | NS | Positive (RNAss) | Negative | A driver for leiomyosarcoma genesis. |
FAF2 | Lung cancers | LUAD and LUSC | Overexpression | Risk | Negative except LUAD RNAss (NS) | NS | Orlistat/Inhibits lung cancer cell proliferation and induces dramatic cell death and apoptosis. |
UBXN1 | BRCA1 tumour | BRCA | NS | NS | Negative (RNAss) | Positive | Regulates the enzymatic function of BRCA1. |
UBXN1 | Glioblastoma | LGG and GBM | NS | Protective | Positive except for LGG DNAss (negative) | Negative | Mediates growth and tumorigenesis. Inhibits tumour growth and tumorigenesis. |
UBXN1 | Colon adenocarcinoma | COAD | NS | NS | - | Negative | Mediates growth and tumorigenesis. Inhibits tumour growth and tumorigenesis. |
UBXN1 | Diffuse gliomas | LGG and GBM | NS | Protective | Positive except for LGG DNAss (negative) | Negative | Mediates proliferation and migration. Regulates protein in EGFRvIII glioma cells. Inhibits tumour progression. |
UBXN1 | Prostate cancer | PRAD | Overexpression | NS | NS | Positive | Mediates proliferation, migration and invasiveness |
UBXN10 | Colon adenocarcinoma | COAD | NS | NS | Positive (RNAss) | NS | Mediates proliferation and migration. Inhibits tumour growth. |
UBXN2A | Colorectal cancer | COAD | NS | NS | Negative (DNAss) | NS | Mediates proliferation and survival. Mediates apoptosis and cell growth. Mediates cell death. Mediates apoptosis and proliferation. Inhibits tumour growth. Inhibits tumour growth. Inhibits proliferation and migration. |
UBXN2A | Osteosarcoma | SARC | – | NS | NS | Negative | Mediates proliferation and migration. |
UBXN7 | Hepatocellular carcinoma | LIHC | Overexpression | Protective | NS | Negative | Mediates tumour formation. |
UBXN7 | Lung squamous cell carcinomas | LUSC | Overexpression | NS | Positive | Negative | Mediates proliferation. |
UBXN8 | Hepatocellular carcinoma | LIHC | Underexpression | NS | Negative | NS | Mediates cell death. |